Rare diseases
Investigational molecules
Locations
Potassium dihydrogen phosphate, also called potassium acid phosphate, is a phosphate salt used as a supplement to correct low phosphate levels in the blood (hypophosphataemia). It is an authorised medicine in the United Kingdom, where it is available as a concentrated injection containing 10 mmol of phosphate per 10 ml.[2] In the registered clinical trial, the substance appears as part of a fixed combination product named COMBINATIONS, in which it is one of many components including amino acids, electrolytes, and glucose.[1] The product is given parenterally, meaning it bypasses the digestive system.[1]
Potassium dihydrogen phosphate provides phosphate, an essential mineral that the body needs for many processes, including energy production, bone health, and muscle function. When blood phosphate levels are low, supplementing with this substance helps restore them. The Nottinghamshire formulary notes that the product is used in the treatment of hypophosphataemia and in refeeding syndrome, a condition where phosphate levels can drop dangerously after a period of malnutrition.[2] In the clinical trial, the substance is being studied for its potential effect on muscle protein turnover in people receiving hemodialysis.[1]
Potassium dihydrogen phosphate is given parenterally, meaning it is delivered directly into the body rather than through the digestive system.[1] In clinical practice, it is available as a concentrated injection containing 10 mmol of phosphate per 10 ml, and in some hospitals as a ready-made infusion containing 9 mmol in a 250 ml bag of sodium chloride 0.9%.[2] The product is restricted to authorised hospital areas and is stored separately from other injectable medicines.[2]
One interventional clinical trial is registered for potassium dihydrogen phosphate as part of the combination product studied. The trial, titled LOTUS, is a Phase 3 study with a planned enrollment of 20 participants.[1] It is currently authorised but not yet recruiting.[1]
The trial investigates the effect of the combination product, referred to as IDPN, on muscle protein synthesis in people with chronic kidney disease receiving hemodialysis. The primary outcome is the difference in myofibrillar fractional synthetic rate during a one-week treatment with IDPN compared with a control. Myofibrillar fractional synthetic rate is a measure of how quickly new muscle protein is being built.[1] The study also aims to characterise the hemodynamic effects of IDPN, meaning its effects on blood flow and blood pressure.[1]
The Nottinghamshire formulary cautions that the rate and concentration recommended for potassium infusions must never be exceeded, as this can be dangerous.[2] Because the concentrated product is treated as a controlled drug and restricted to authorised areas, it requires careful handling.[2] No further side effect information is provided in the available sources.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
